An inconsistent supply of medicine can negatively impact a patient’s health in numerous ways that are often complex.
Drug shortages have been cited as a public health threat by organizations including the Government Accountability Office, which reports that most shortages are a result of manufacturers halting or slowing production to address quality problems, therefore triggering a supply disruption. As of October 2016, the US Food and Drug Administration’s (FDA) Drug Shortage Program listed 63 drugs in short supply. As the above chart shows, Amgen has had zero drug shortages between 2011 and 2015.
At Amgen, this issue is personal, and our history of reliability speaks for itself. In over 30 years of manufacturing biologic medicines, our company has developed a strong track record of incredibly consistent supply. We strive to ensure that the patients we serve — including our own employees and their families — do not have their treatment disrupted for any reason. We pride ourselves on the ability to scale our manufacturing up or down as rapidly as necessary to accommodate varying demand levels.
Biotechnology by Amgen is the story of what it takes to deliver biotechnology medicines to patients. It’s a program dedicated to raising awareness about the incredible complexity of biotechnology manufacturing.
Amgen has a strong commitment to quality and reliability, has made significant, long-term investments in biologics manufacturing, and has a broad and deep knowledge of biotechnology that comes with having developed and manufactured a diverse portfolio of biotechnology medicines.